Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Palwasha Y. Khan, Molly F. Franke, Catherine Hewison, Kwonjune J. Seung, Helena Huerga, Sidney Atwood, Saman Ahmed, Munira Khan, Tanha Sultana, Mohammad Manzur-ul-Alam, Luan N.Q. Vo, Leonid Lecca, Kalkidan Yae, Serik Kozhabekov, Meseret Tamirat, Alain Gelin, Stalz C. Vilbrun, Marina Kikvidze, Jamil Faqirzai, Abdullaat Kadyrov, Alena Skrahina, Anita Mesic, Nana Avagyan, Mathieu Bastard, Michael L. Rich, Uzma Khan, Carole D. Mitnick. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020

Member's Comments

No comment yet.

Related content which might interest you: The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700463; 10.1183/13993003.00463-2017 Year: 2017 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700228; 10.1183/13993003.00228-2017 Year: 2017 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 Poor treatment outcomes of XDR-TB patients in resource-limited settings Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019 Year: 2020 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47: 1235-1243 Year: 2016 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021